GIMAP4 and neoplasm: Generally, GIMAP4 might act as an anti-tumor biomarker, a predictor for survival and immunotherapy response, and make contributions to representing the immune-dominant state in TME of CC according to the following facts that the upregulation of GIMAP4 along with the higher survival rate, early M classification of CC, the status conversion of TME from metabolism to immune, and the increment of anti-tumor TICs and ICPs.